endovastec™ gained nmpa approval for minos™abdominal aortic stent-云顶国际

shanghai microport endovascular medtech co., ltd.（endovastec™）recently announced that it has gained china nmpa (national medical products administration) approval for its in-house developed minos™abdominal aortic stent-graft and delivery system (minos™), which marked a formal clearance for entering the chinese market.

minos™ is designed for endovascular aneurysm repair (evar) to treat abdominal aortic aneurysm with proximal neck length no less than 15mm. its ultra-low profile delivery system with 14f od offers a better option for the patients who were previously considered ineligible for an evar procedure due to smaller, tortuous, or calcified access vessel arteries. minos™ features a three-piece design which enables in situ customization, allowing a 25-35mm or 25mm-55mm stent overlap for adjustment during operation. its main body was constructed from a laser-cut bare stent with integrated barbs and mini-waved stents covered with seamless woven graft, and its iliac limbs are woven by a single wire in a spiral pattern. the unique design ensures a high flexibility even during the treatment of patients with complex anatomies, and reduces the rate of complications including endoleaks or device migration or occlusion, thus presents a lower risk of reintervention.

according to related articles, abdominal aortic aneurysm is often paralleled by atherosclerotic and hypertension which could be risk factors of calcification, tortuosity, stenosis and even total occlusion in access vessels. the low profile system can potentially address these concerns, and furthermore, the stent graft itself owns superior performance in reducing complications like endograft migration or endoleaks which are caused by short or twisted neck aneurysm.

“the approval of minos™ stent graft system will provide patients with complicated abdominal aortic anatomies with better solutions, especially benefiting patients with narrow and tortuous access arteries. innovation has been rooted in endovastec™ and the company is committed to deliver more innovative medical solutions for patients”, said president zhenghua miao from endovastec™.